statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus rating of "Buy" by the four research firms that are covering the company, MarketBeat Ratings reports. Four investment...

Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $3.80

ProQR Therapeutics (NASDAQ:PRQR  Get Free Report) had its target price lifted by Chardan Capital from $2.00 to $2.50 in a note issued to investors on Thursday, Benzinga reports. The brokerage...

Chardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ProQR Therapeutics sees cash runway into mid-2026

ProQR Therapeutics reports 2023 EPS (EUR 0.35) vs. (EUR 0.90) last year

Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Therapeutics (NASDAQ:PRQR  Get Free Report) has been assigned a consensus rating of Buy from the five research firms that are covering the company, Marketbeat Ratings...

ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies...

ProQR Announces Japanese Axiomer  Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

ProQR Therapeutics (NASDAQ:PRQR  Get Free Report) was upgraded by equities research analysts at StockNews.com from a hold rating to a buy rating in a report...

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at StockNews.com

Shares of ProQR Therapeutics (NASDAQ:PRQR  Get Free Report) have received a consensus recommendation of Buy from the five ratings firms that are covering the firm, Marketbeat...

ProQR Therapeutics (NASDAQ:PRQR  Get Free Report) was downgraded by equities researchers at StockNews.com from a buy rating to a hold rating in a report released on...

StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Hold

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

Volume	43,209.00
52-Wk High	$3.29
52-Wk Low	$1.11

PRQR ProQR Therapeutics N.V

About

Feed

News

Earnings

Fundamentals